Breaking News, Collaborations & Alliances

Bio Immunitas Enters Manufacturing Collaboration with GenScript ProBio

The partnership will fast-track Bio Immunitas' manufacturing and production from bench to bedside in an expedited timescale while maintaining regulatory milestones.

GenScript ProBio, a biologics contract development and manufacturing organization (CDMO) to the biopharmaceutical market, and Bio Immunitas, a UK pharmaceutical company with a novel, safe and efficacious human Recombinant Protein Platform (hRPP), announced a partnership for developing potential novel therapies for clinical use. 

The long-term partnership will fast-track Bio Immunitas’ manufacturing and production from bench to bedside in an expedited timescale while maintaining regulatory milestones.

GenScript ProBio provides IND-enabling CMC services for Bio Immunitas to accelerate the preclinical development of 2 recombinant protein products using Bio Immunitas’ proprietary hRPP platform.

“This relationship will help us realize our commitment to creating innovative, differentiated treatments for millions of patients,” said Syed Haq, CEO/CMO of Bio Immunitas.

Brian Min, the CEO of GenScript ProBio, said, “We’re delighted to collaborate with Bio Immunitas to accelerate its novel therapeutic platform and expect more patients will benefit from this superior treatment.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters